Balchem earnings release, October 23, 2026

Balchem Corp (BCPC) · Form 8-K, Item 2.02 · Filed · SEC filing

Balchem Corporation Reports Third Quarter 2026 Financial Results

Montvale, NJ, October 23, 2026

- Balchem Corporation (NASDAQ: BCPC) today reported financial results for its 2026 fiscal third quarter ended September 30, 2026. For the quarter, the Company reported net sales of $290.7 million, net earnings of $46.7 million, adjusted EBITDA

Financial statements

Income Statement

Three Months Ended September 30, — (Dollars in thousands, except per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net sales290,658267,558845,364773,544
Gross margin105,71495,453310,481276,734
Operating expenses43,27740,874133,197119,698
Earnings from operations62,43754,579177,284157,036
Interest and other expenses2,3932,5356,9378,041
Earnings before income tax expense60,04452,044170,347148,995
Income tax expense13,31611,75538,71933,375
Net earnings46,72840,289131,628115,620
Diluted net earnings per common share1.461.244.093.54
Adjusted EBITDA(a)80,29771,447232,522206,961
Adjusted net earnings(a)50,35043,982141,437125,560
Adjusted net earnings per common share(a)1.571.354.43.84
Shares used in the calculations of diluted and adjusted net earnings per common share32,03232,59532,18132,702

Income Statement

Three Months Ended September 30, — (Dollars in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net earnings - as reported46,72840,289131,628115,620
Add back:Provision for income taxes13,31611,75538,71933,375
Add back:Interest and other expenses2,3932,5356,9378,041
Add back:Depreciation and amortization12,28811,48136,85533,753
Add back:EBITDA74,72566,060214,139190,789
Add back:Non-cash compensation expense related to equity awards5,0394,65016,31614,298
Add back:Transaction and integration costs (2)5783331,4951,227
Add back:Nonqualified deferred compensation plan expense (3)-45404572839
Add back:Restructuring costs (4)-192
Add back:Adjusted EBITDA80,29771,447232,522206,961

Income Statement

Three Months Ended September 30, — (Dollars in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – Effective Tax RateThree Months Ended September 30, – 2025Three Months Ended September 30, – Effective Tax Rate
GAAP Income Tax Expense13,31622.211,75522.6
Impact of ASU 2016-09 (6)26021
Adjusted Income Tax Expense13,57622.611,77622.6

Income Statement

Nine Months Ended September 30, — (Dollars in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – Effective Tax RateNine Months Ended September 30, – 2025Nine Months Ended September 30, – Effective Tax Rate
GAAP Income Tax Expense38,71922.733,37522.4
Impact of ASU 2016-09 (6)1,550894
Adjusted Income Tax Expense40,26923.634,26923

Balance Sheet

Selected Balance Sheet Items — Balchem Corporation (NASDAQ:BCPC) (in thousands)

September 30, 2026 – (unaudited)December 31, 2025
Cash and cash equivalents66,26474,570
Accounts receivable, net145,635143,596
Inventories177,006131,449
Other current assets15,97215,999
Total current assets404,877365,614
Property, plant and equipment, net306,135306,648
Goodwill807,487816,375
Intangible assets with finite lives, net147,366163,289
Right of use assets17,68316,192
Other assets20,02418,134
Total non-current assets1,298,6951,320,638
Total assets1,703,5721,686,252
Current liabilities164,115176,384
Revolving loan124,000164,000
Deferred income taxes52,27354,143
Other long-term obligations36,40734,312
Total liabilities376,795428,839
Stockholders' equity1,326,7771,257,413
Total liabilities and stockholders' equity1,703,5721,686,252

Cash Flow

Nine Months Ended September 30, — (unaudited)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:Net earnings131,628115,620
Adjustments to reconcile net earnings to net cash provided by operating activities:Depreciation and amortization37,10033,969
Adjustments to reconcile net earnings to net cash provided by operating activities:Stock compensation expense16,31614,298
Adjustments to reconcile net earnings to net cash provided by operating activities:Other adjustments3,037-1,692
Adjustments to reconcile net earnings to net cash provided by operating activities:Changes in assets and liabilities-31,537-12,914
Adjustments to reconcile net earnings to net cash provided by operating activities:Net cash provided by operating activities156,544149,281
Cash flows from investing activities:Capital expenditures and intangible assets acquired-29,605-27,275
Cash flows from investing activities:Cash paid for acquisitions, net of cash acquired-323
Cash flows from investing activities:Proceeds from the sale of assets7267
Cash flows from investing activities:Investment in affiliates-155-144
Cash flows from investing activities:Net cash used in investing activities-29,753-27,475
Cash flows from financing activities:Proceeds from revolving loan88,00070,000
Cash flows from financing activities:Principal payments on revolving loan-128,000-106,000
Cash flows from financing activities:Principal payments on finance leases-153-145
Cash flows from financing activities:Cash paid for financing costs-1,943
Cash flows from financing activities:Proceeds from stock options exercised11,5896,867
Cash flows from financing activities:Dividends paid-30,773-28,276
Cash flows from financing activities:Repurchases of common stock-71,925-54,008

Cash Flow

Three Months Ended September 30, — (Dollars in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net cash provided by operating activities69,77265,572156,544149,281
Capital expenditures and proceeds from the sale of assets-11,863-14,891-28,559-26,866
Free cash flow57,90950,681127,985122,415
Full release

(a) of $80.3 million, and free c ash flow

(a) of $57.9 million.

Ted Harris, Chairman, President and CEO of Balchem, said, “Balchem delivered another excellent quarter, with healthy growth across all three of our reporting segments and record consolidated quarterly net sales, net earnings, and adjusted EBITDA.”

Third Quarter 2026 Financial Highlights:

• Net sales were $290.7 million, an increase of 8.6% from the prior year quarter.

• GAAP net earnings were $46.7 million, an increase of 16.0% from the prior year quarter.

• Adjusted EBITDA was $80.3 million, an increase of 12.4% from the prior year quarter.

• GAAP earnings per share were $1.46 compared to $1.24 in the prior year quarter and adjusted earnings per share

(a) were $1.57 compared to $1.35 in the prior year quarter.

• Cash flows from operations were $69.8 million, with free cash flow of $57.9 million.

• Sales and earnings from operations growth in all three of our reporting segments.

Recent Highlights:

• At the upcoming SupplySide Global trade show, we will showcase several of our latest Human Nutrition and Health technologies and innovations, including new science supporting VitaCholine®, K2VITAL™, Optifolin+® and OptiMSM®, as well as advances in performance nutrition and functional food and beverage applications. These innovations highlight the strength of our pipeline and our continued focus on developing differentiated, science-backed solutions that address important human health and wellness trends.

• Balchem repurchased approximately $28 million of common stock during the third quarter and approximately $127 million over the trailing twelve months, reflecting the Company's balanced capital allocation strategy and commitment to long-term shareholder value creation.

Mr. Harris added, “With strong results through the first nine months of the year and a healthy balance sheet, Balchem is well positioned to continue executing our strategic growth initiatives, and we remain excited about the future of our company.”

Balchem Corporation (NASDAQ:BCPC)

Results for Period Ended September 30, 2026 (unaudited)

(Dollars in thousands, except per share data)

Balchem Corporation (NASDAQ:BCPC)

Financial Results for the Third Quarter of 2026:

The

Human Nutrition and Health segment generated record quarterly sales of $188.2 million, an increase of $14.1 million, or 8.1%, compared to the prior year quarter. The increase was driven by higher sales within both the nutrients business and the food ingredients and solutions businesses. Record earnings from operations for this segment of $45.6 million increased $4.8 million, or 11.8%, compared to $40.8 million in the prior year quarter, primarily due to the aforementioned higher sales and favorable mix, partially offset by higher operating expenses. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, record adjusted earnings from operations

(a) for this segment were $48.9 million, compared to $44.1 million in the prior year quarter, an increase of 10.9%.

The

Animal Nutrition and Health segment generated quarterly sales of $63.0 million, an increase of $6.6 million, or 11.7%, compared to the prior year quarter. The increase was driven by higher sales in both the monogastric and ruminant species markets. Third quarter earnings from operations for this segment of $6.8 million increased $3.1 million, or 82.8%, compared to $3.7 million in the prior year quarter, primarily due to the aforementioned higher sales and favorable mix, partially offset by certain higher manufacturing input costs. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, adjusted earnings from operations for this segment were $7.0 million compared to $4.0 million in the prior year quarter, an increase of 73.6%.

The

Specialty Products segment generated quarterly sales of $37.3 million, an increase of $1.6 million, or 4.5%, compared to the prior year quarter, due to higher sales in the performance gases business. Earnings from operations for this segment of $12.3 million increased $0.8 million, or 6.6%, compared to $11.5 million in the prior year quarter, primarily driven by the aforementioned higher sales and favorable mix, partially offset by higher operating expenses. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets and other adjustments, adjusted earnings from operations for this segment were $13.1 million, compared to $12.7 million in the prior year quarter, an increase of 3.0%.

Consolidated quarterly gross margin of $105.7 million increased by $10.3 million, or 10.7%, compared to $95.5 million for the prior year comparable period. Gross margin as a percentage of sales was 36.4% compared to 35.7% in the prior year period, an increase of 70 basis points, primarily due to sales growth, favorable mix and manufacturing efficiencies, partially offset by certain higher manufacturing input costs. Operating expenses of $43.3 million for the quarter increased $2.4 million from the prior year comparable quarter, primarily due to higher compensation-related costs, partially offset by the net favorable impact of certain discrete items.

Net interest expense was $1.9 million and $2.6 million in the third quarters of 2026 and 2025, respectively.

The decrease in interest expense was primarily due to lower outstanding borrowings and lower interest rates.

Our effective tax rates for the three months ended September 30, 2026 and 2025 were

22.2% a nd 22.6%, respectively... (truncated)ctive tax rate was primarily d ue to higher favorable adjustments related to the filing of the prior year federal tax return and a higher foreign-derived intangible income deduction benefit, partially offset by an increase in certain state taxes.

Third quarter cash flows provided by operating activities were $69.8 million and free cash flow was $57.9 million. Net working capital of $240.8 million as of September 30, 2026 included a cash balance of $66.3 million. Significant cash payments during the quarter included net debt payments of $28.0 million, income taxes paid of $27.8 million, repurchases of common stock of $27.4 million, and capital expenditures and intangible assets acquired of $12.5 million. Outstanding debt on our revolving loan was $124.0 million as of September 30, 2026 and our net debt

(b) was $57.7 million, with an overall leverage ratio

(c) on a net debt basis of 0.2 times.

Mr. Harris said, “The Balchem team delivered another strong quarter in Q3 of 2026, and we remain confident in the long-term growth outlook for our company as we continue to execute our strategic growth initiatives.”

Balchem Corporation (NASDAQ:BCPC)

Quarterly Conference Call

A quarterly conference call will be held on Friday, October 23, 2026, at 11:00 AM Eastern Time (ET) to review third quarter 2026 results. Ted Harris, Chairman, President and CEO and Martin Bengtsson, CFO, will host the call. Institutional investors, analysts and other members of the financial community are invited to join the live call by dialing +1-833-461-5787 (USA/Canada toll free) or +1-585-542-9983 (International Toll), and referencing Meeting ID: 831870284, five minutes prior to the scheduled start time of the conference call. Investors and the public are invited to listen to the live webcast at https://events.q4inc.com/attendee/831870284. The conference call will be available for replay shortly after the conclusion of the call at https://events.q4inc.com/attendee/831870284 for one year.

Segment Information

Balchem Corporation reports three business segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition and Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition and Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged performance gases for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".

Forward-Looking Statements

This release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. Forward-looking statements may relate to such matters as projections of revenue, margins, expenses, tax provisions, earnings, cash flows, benefit obligations, dividends, share repurchases or other financial items; any statements of the plans, strategies and objectives of management for future operations, including those relating to any statements concerning expected development, performance or market share relating to our products and services; any statements regarding future economic conditions or our performance; any statements regarding pending investigations, claims or disputes; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. These statements are based on the Company's currently available information and our current assumptions, expectations and projections about future events. They are subject to future events, risks and uncertainties - many of which are beyond the Company’s control - as well as potentially inaccurate assumptions, that could cause actual results to differ materially from those in the forward-looking statements. Important factors and other risks that may affect the Company's business or that could cause actual results to differ materially are included in filings the Company makes with the U.S. Securities and Exchange Commission from time to time, including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, its Current Reports on Form 8-K, and in its other SEC filings. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Jacqueline Yarmolowicz, Balchem Corporation (Telephone: 845-326-5600)

Balchem Corporation (NASDAQ:BCPC)

Selected Financial Data (unaudited)

($ in 000’s)

Balchem Corporation (NASDAQ:BCPC)

Balchem Corporation (NASDAQ:BCPC)

Balchem Corporation

Condensed Consolidated Statements of Cash Flows

(Dollars in thousands)

(unaudited)

Balchem Corporation (NASDAQ:BCPC)

Non-GAAP Financial Information... (truncated)t we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted diluted per share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, free cash flow, net debt, and leverage ratio. The non-GAAP financial measures disclosed by the Company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain equity compensation, nonqualified deferred compensation plan expense (income), and certain one-time or unusual transactions. Detailed non-GAAP adjustments are described in the reconciliation tables below and also explained in the related footnotes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Investors should not consider non-GAAP measures as alternatives to the related GAAP measures.

Set forth below are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

Table 1

(unaudited)

Reconciliation of Non-GAAP Measures to GAAP

(Dollars in thousands, except per share data)

Balchem Corporation (NASDAQ:BCPC)

Table 2

(unaudited)

Reconciliation of GAAP Net Earnings to EBITDA and to Adjusted EBITDA

(Dollars in thousands)

Table 3

(unaudited)

Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income Tax Rate

(Dollars in thousands)

Balchem Corporation (NASDAQ:BCPC)

Table 4

(unaudited)

Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow

(Dollars in thousands)

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.